Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Associations between sex, IM history, HLA-DR15 genotype, HLA-A2 genotype, 25(OH)D, UVR exposure and age of symptom onset.

Source: Sex, HLA-DR15, HLA-A2 and history of infectious mononucleosis. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The Ausimmune Study was an Australian multicenter case-control study ().

Source: Methods.

Case participants were aged 18 to 59 years and resident in a study region: Brisbane city (latitude 27° South), Newcastle city and surrounds (33°S), Geelong city and the Western Districts of Victoria (37° S), or the state of Tasmania (~41 to 43°S).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset

Case-control study · Frontiers in Neurology · 2018

Original publication title

Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset

Chunrong Tao; Steve Simpson Jr.; Bruce V. Taylor; Leigh Blizzard; Robyn M. Lucas; Anne-Louise Ponsonby; Simon Broadley; AusLong/Ausimmune Investigators GroupLucasRobyn MDearKeithPonsonbyAnne-LouiseDwyerTerryvan der MeiIngridBlizzardLeighSimpsonSteveJr.TaylorBruce VBroadleySimonKilpatrickTrevorWilliamsDavidLechner-ScottJeanetteShawCameronChapmanCaronCoulthardAlanPenderMichael PValeryPatricia; Ingrid van der Mei

Copyright © 2018 Tao, Simpson, Taylor, Blizzard, Lucas, Ponsonby, Broadley, AusLong/Ausimmune Investigators Group and van der Mei.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Conclusion:

We found a novel association between a history of tobacco smoking and later onset, whereas marijuana use was associated with earlier onset. Behavioral factors seem important drivers of MS onset timing although much of the variance remains unexplained.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Examine the associations between known or emerging MS risk factors and ASO.

Source: Objective:

Abstract: What methods does the paper describe?

This was a multicenter study, incident cases (n = 279) with first clinical diagnosis of demyelinating event aged 18 to 59 years recruited at four Australian centres (latitudes 27°-43°S), from 1 November 2003 to 31 December 2006. Environmental/behavioral variables and initial symptoms were recorded at baseline interview. Linear regression was used to assess the association between risk factors and ASO.

Source: Methods:

Abstract: Results

Five factors were significantly associated with ASO: a history of tobacco smoking was associated with 3.05-years later ASO (p = 0.002); a history of marijuana use was associated with 6.03-years earlier ASO (p < 0.001); progressive-onset cases had 5.61-years later ASO (p = 0.001); an initial presentation of bowel & bladder and cerebral dysfunctional were associated with 3.39 (p = 0.017) and 4.37-years (p = 0.006) later ASO, respectively. Other factors, including sex, offspring number, latitude of study site, history of infectious mononucleosis, HLA-DR15 & HLA-A2 genotype, 25(OH)D levels, and ultraviolet radiation exposure were not associated with ASO. Including all five significant variables into one model explained 12% of the total variance in ASO.

Source: Results:

Abstract: Conclusion

We found a novel association between a history of tobacco smoking and later onset, whereas marijuana use was associated with earlier onset. Behavioral factors seem important drivers of MS onset timing although much of the variance remains unexplained.

Source: Conclusion:
Authors’ abstract

Background:

Age at symptom onset (ASO) is a prognostic factor that could affect the accrual of disability in multiple sclerosis (MS) patients. Some factors are known to influence the risk of multiple sclerosis (MS), but their influence on the ASO is less well-investigated.

Objective:

Examine the associations between known or emerging MS risk factors and ASO.

Methods:

This was a multicenter study, incident cases (n = 279) with first clinical diagnosis of demyelinating event aged 18 to 59 years recruited at four Australian centres (latitudes 27°-43°S), from 1 November 2003 to 31 December 2006. Environmental/behavioral variables and initial symptoms were recorded at baseline interview. Linear regression was used to assess the association between risk factors and ASO.

Results:

Five factors were significantly associated with ASO: a history of tobacco smoking was associated with 3.05-years later ASO (p = 0.002); a history of marijuana use was associated with 6.03-years earlier ASO (p < 0.001); progressive-onset cases had 5.61-years later ASO (p = 0.001); an initial presentation of bowel & bladder and cerebral dysfunctional were associated with 3.39 (p = 0.017) and 4.37-years (p = 0.006) later ASO, respectively. Other factors, including sex, offspring number, latitude of study site, history of infectious mononucleosis, HLA-DR15 & HLA-A2 genotype, 25(OH)D levels, and ultraviolet radiation exposure were not associated with ASO. Including all five significant variables into one model explained 12% of the total variance in ASO.

Conclusion:

We found a novel association between a history of tobacco smoking and later onset, whereas marijuana use was associated with earlier onset. Behavioral factors seem important drivers of MS onset timing although much of the variance remains unexplained.

Publication and source details

Original title: Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset

Chunrong Tao; Steve Simpson Jr.; Bruce V. Taylor; Leigh Blizzard; Robyn M. Lucas; Anne-Louise Ponsonby; Simon Broadley; AusLong/Ausimmune Investigators GroupLucasRobyn MDearKeithPonsonbyAnne-LouiseDwyerTerryvan der MeiIngridBlizzardLeighSimpsonSteveJr.TaylorBruce VBroadleySimonKilpatrickTrevorWilliamsDavidLechner-ScottJeanetteShawCameronChapmanCaronCoulthardAlanPenderMichael PValeryPatricia; Ingrid van der Mei

Frontiers in Neurology · 2018

Edited by: Robert Weissert, University of Regensburg, Germany

Reviewed by: Maria José Sá, Centro Hospitalar São João, Portugal; Moussa Antoine Chalah, Hôpitaux Universitaires Henri Mondor, France

*Correspondence: Ingrid van der Mei ingrid.vandermei@utas.edu.au

This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology

Copyright © 2018 Tao, Simpson, Taylor, Blizzard, Lucas, Ponsonby, Broadley, AusLong/Ausimmune Investigators Group and van der Mei.2018Tao, Simpson, Taylor, Blizzard, Lucas, Ponsonby, Broadley, AusLong/Ausimmune Investigators Group and van der Meihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.National Multiple Sclerosis Society10.13039/100000890RG3364A1/2National Health and Medical Research Council10.13039/501100000925APP316901224215

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:25:59.953793+00:00

DOI: 10.3389/fneur.2018.00418 · PMC6003245